AXSM · XBRL financial data

Axsome Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (AXSM's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	72*	75	87	105	119*	121	150	171	196*	191	218	260
Research and development	31*	37	50	45	55*	45	50	40	49*	53	46	51
Selling, general and administrative	87*	99	104	96	113*	121	130	150	169*	185	208	203
General and administrative	year only	12	13	12	18*	12	13	20	19*	22	25	18
Operating income (loss)	(98)*	(67)	(78)	(63)	(73)*	(57)	(37)	(46)	(27)*	(63)	(50)	(11)
Interest expense	year only	(5)	(5)	(6)	(5)*	(5)	(4)	(3)	(3)*	3	(3)	(3)
Income tax expense (benefit)	(0)*	0	0	0	0*	0	(1)	0	0*	0	0	0
Net income (loss)	(99)*	(68)	(79)	(65)	(75)*	(59)	(48)	(47)	(29)*	(65)	(51)	(13)
Earnings per share, basic USD per share	(2.08)*	(1.44)	(1.67)	(1.34)	(1.54)*	(1.22)	(0.97)	(0.94)	(0.56)*	(1.26)	(0.99)	(0.25)
Earnings per share, diluted USD per share	(2.08)*	(1.44)	(1.67)	(1.34)	(1.54)*	(1.22)	(0.97)	(0.94)	(0.56)*	(1.26)	(0.99)	(0.25)
Weighted average shares, basic millions of shares	47*	47	48	48	49*	49	49	50	51*	51	52	52
Weighted average shares, diluted millions of shares	47*	47	48	48	49*	49	49	50	51*	51	52	52

Fiscal quarters (AXSM's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	386	331	316	327	315	301	303	325	323	305	320	314
Accounts receivable	95	101	120	124	142	161	199	197	224	251	277	343
Inventory	15	16	15	14	16	16	18	24	28	32	38	43
Prepaid and other current assets	8	12	12	13	12	16	16	20	14	24	21	25
Total current assets	504	460	463	479	485	495	537	565	589	611	657	725
Property and equipment, net	1	1	1	1	1	1	1	1	1	1	1	1
Right-of-use asset	7	6	6	6	5	23	22	22	21	20	19	18
Goodwill	12	12	12	12	12	12	12	12	12	12	12	12
Total assets	588	546	548	561	568	597	640	669	690	714	761	827
Accounts payable	41	54	61	64	72	86	92	54	66	107	79	96
Current portion of long-term debt	—	—	—	—	0	—	70	70	70	70	70	70
Total current liabilities	139	144	187	196	230	244	342	360	379	439	460	510
Long-term debt	178	179	179	180	181	181	118	118	118	118	118	118
Lease liability, non-current	7	7	7	6	6	24	24	23	23	22	22	21
Total liabilities	397	402	445	469	511	543	567	596	602	659	678	721
Accumulated deficit	(836)	(904)	(983)	(1,048)	(1,123)	(1,182)	(1,230)	(1,277)	(1,306)	(1,371)	(1,422)	(1,435)
Total stockholders' equity	191	144	103	93	57	53	73	74	88	55	83	105
Total liabilities and equity	588	546	548	561	568	597	640	669	690	714	761	827
Common shares outstanding (cover page) millions of shares	47	47	48	48	49	49	50	50	51	51	52	53

Fiscal quarters (AXSM's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(99)*	(68)	(79)	(65)	(75)*	(59)	(48)	(47)	(29)*	(65)	(51)	(13)
Stock-based compensation	19*	20	21	22	22*	23	25	23	23*	23	27	26
Net cash from operating activities	(30)*	(53)	(30)*	(19)*	(26)*	(43)	(32)*	1*	(19)*	(21)	(33)*	(9)*
Purchases of property and equipment	0*	0	0*	0*	0*	0	0*	0*	0*	0	0*	0*
Net cash from investing activities	(0)*	(0)	(0)*	(0)*	(0)*	(0)	(0)*	(0)*	(0)*	(0)	(0)*	(0)*
Proceeds from issuing common stock	0*	—	—	13*	16*	20	33*	10*	6*	6	13*	0*
Repayments of long-term debt	—	—	—	—	—	—	—	70*	70*	70	70*	70*
Net cash from financing activities	(0)*	(1)	14*	30*	14*	29	35*	21*	16*	3	48*	4*
Net change in cash	(30)*	(55)	(16)*	12*	(12)*	(14)	2*	22*	(2)*	(18)	15*	(6)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Axsome Therapeutics	314	260	(9.5)*	52.6M	14.7 quarters	Q3 FY26 10-QSep 30, 2026
Halozyme Therapeutics	163	481	241*	113.5M	—	Q2 FY26 10-QJun 30, 2026
Lantheus Holdings	593	388	92*	65.3M	—	Q2 FY26 10-QJun 30, 2026
Adma Biologics	136	124	30*	224.0M	—	Q2 FY26 10-QJun 30, 2026
Alkermes	631	480	93*	168.0M	—	Q3 FY26 10-QSep 30, 2026
Soleno Therapeutics	133	not reported	26	52.1M	—	Q1 FY26 10-QMar 31, 2026
Rhythm Pharmaceuticals	40	92	(3.1)*	69.3M	16.9 quarters	Q3 FY26 10-QSep 30, 2026
Vaxcyte	183	not reported	(232)*	148.8M	6.4 quarters	Q2 FY26 10-QJun 30, 2026
Ionis Pharmaceuticals	350	268	566*	166.2M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.